Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Invesco QQQ

O'Reilly Automotive

U.S. indices bounced off Monday morning's lows as investors weigh weak China retail and production data. Uncertainty around the COVID-19 Delta variant is also weighing on the market.

DexCom And O'Reilly Auto Parts Lead The QQQ Monday

FedEx

These companies are still going to be great long-term buys.

3 Growth Stocks to Buy and Hold Regardless of What Happens With the Delta Variant

Pinterest

These two stocks have been moving in opposite directions of late.

2 Top Growth Stocks That Could Help Your Portfolio Shine

Lululemon Athletica

Insulet

Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.

3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain

KLA-Tencor

Many investors probably haven't even have heard of these big winners.

These 2 Winning Stocks Came Out of Nowhere Friday

Continuous glucose monitor developer Dexcom Inc (NASDAQ: DXCM) shares ticked up as second-quarter results easily topped the consensus forecast; adjusted EPS of 0.76 beat the consensus of $0.45. Sales increased 32% Y/Y $595.1 million, well ahead of the estimate of $551.3 million.

Dexcom Stock Jumps As Q2 Earnings Beats Street, Raises Guidance; Analysts Bump Up Target Price

Wall Street is thrilled with acceleration out of the pandemic and a new product on the horizon.

Why Shares of Dexcom Are Gaining This Morning

DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

DexCom, Inc. (DXCM) CEO Kevin Sayer on Q2 2021 Results - Earnings Call Transcript

Shares of DexCom (NASDAQ:DXCM) rose 3.7% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 3.80% year over year to $0.76, which beat the estimate of $0.45.

Recap: DexCom Q2 Earnings

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Reports Second Quarter 2021 Financial Results

Dexcom Reports Second Quarter 2021 Financial Results

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate DexCom (DXCM) to Report a Decline in Earnings: What to Look Out for

Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.

Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #API--FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

SAN DIEGO--(BUSINESS WIRE)-- #dxcm--Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time

Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time

The shares of DexCom, Inc. (NASDAQ: DXCM) have received a price target of $468 from Stephens. These are the details.

DXCM Stock Price: $468 Target From Stephens

SAN DIEGO--(BUSINESS WIRE)-- #ADA--Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

Medtronic

Tandem Diabetes Care

CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes

DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes

Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days.

Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels

Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.

Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia

BURNABY, British Columbia--(BUSINESS WIRE)---- $DXCM #cgm--Dexcom announces that people with diabetes may now be eligible for provincial coverage of the Dexcom G6 CGM System through BC PharmaCare.

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Looks to the Future of Continuous Glucose Monitoring

Dexcom Looks to the Future of Continuous Glucose Monitoring

Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0 Somewhat Bullish 0 2 1 0 Indifferent 1 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 9 analysts offering 12-month price targets in the last 3 months for DexCom evaluate the company at an average price target of $451.78 with a high of $500.00 and a low of $380.00.

News for DexCom Stock (DXCM)